IndustryCompany release

Baxter lifts 2026 guidance after third-quarter sales rise 5% to $2.98bn

🇺🇸 Baxter International Inc (BAX) · Thu 29 Oct 2026

The medtech group reported growth both as reported and organically, a lower adjusted profit on a higher tax rate, and the retirement of $864m of debt through a tender offer.

Baxter International reported third-quarter 2026 results on 29 October, with sales of about $2.98bn. Sales rose 5% on both a reported and an organic basis, according to the company's headline summary.

Profit per share was lower on an adjusted basis. GAAP diluted earnings per share were $0.57, while adjusted earnings per share were $0.58, down 16% year on year. The company attributed the fall to a higher tax rate.

On the strength of the quarter, Baxter raised its full-year outlook. It now expects 2026 reported sales growth of 4% to 5% and adjusted earnings per share of $2.05 to $2.15.

Baxter also completed a cash tender offer of $600m, through which it retired $864m of debt. The summary available does not give further detail on the terms of the offer, segment-level figures or the previous guidance range.

What it means for your team

  • Market-access and commercial teams working with Baxter can read the higher guidance as the company expecting stronger full-year sales growth than it previously projected.
  • Supply and procurement teams may want to follow the company's full results for segment detail, as the summary does not break down performance by product line.
  • The debt reduction is a balance-sheet development with no direct regulatory or pharmacovigilance implications in the information available.

Company's press release (SEC filing): Baxter International Inc ↗

Article written by VigiEye from the official source (Baxter International Inc). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →